Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

This study has been withdrawn prior to enrollment.
(Withdrawn by PI due to insufficient accrual)
Sponsor:
Collaborator:
Novartis
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00230334
First received: September 28, 2005
Last updated: April 11, 2011
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given